AtTEnd final PFS analysis manuscript published in The Lancet Oncology
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology - Available online 2 August 2024